|
|
169 Union Blvd.
Totowa, NJ 07512 USA
phone:973-768-0402
fax:
|
|
| Symbol |
Private |
| Founded |
2008 |
| Employees |
2 |
|
|
| www.vectracor.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Medical device to treat cardiac and neurological diseases. |
|
| Management |
| David M. Schreck, MD, MS, FACP, FACEP - Chairman & CMO; Brad Schreck, MS MBA President |
| |
|
|
| |
|
| Keywords |
| device, cardiology, neurology |
|
|
|
| Description |
|
VectraCor's mission is to develop and commercialize a portfolio of products that utilize its patented intellectual property, simplifying and providing a faster method for diagnosis, prevention, and treatment of cardiac and neurological diseases. |
|
| Products / Services |
VectraplexECG Monitor
Vectraplex Holter Monitor
|
|
| Technology / Differentiation |
| A common complication of an acute myocardial infarction (heart attack, AMI) is the development of life threatening arrhythmias. In order to prevent life threatening arrhythmias, it is greatly advantageous to be able to detect the onset of an AMI before the arrhythmia develops. Therefore if not treated properly, an AMI may develop an arrhythmias which may be life threatening. VectraCor is the first company to develop and patent novel signal processing algorithms to diagnose a heart attack within seconds. This major diagnostic advancement will improve the delivery of life-saving treatments and help reduce the long term growth of health care costs in patients with cardiovascular disease (CVD). In addition, VectraCors technology will be able to improve the current mature cardiac monitoring market by actually deriving a 12-22 lead ECG directly from the cardiac monitor using the placement of just 5 electrodes, instead of using a separate dedicated ECG machine.
VectraCors technology incorporates the worlds first patented Cardiac Electrical Biomarker (VectraplexAMI) that in real-time will diagnose an AMI. No other company has yet developed such a technology. The goal is to incorporate the technology in a cardiac monitor as a number in real-time, similar to the heart rate. If the patient begins to develop an AMI, the VectraplexAMI will change, setting up an alarm and allow the physician to view/print in real time the derived 12-22 lead ECG for immediate interpretation.
The current ER practice of chest pain evaluation is to connect the patient to a continuous cardiac rhythm monitor (3-5 electrodes), then connect an additional ECG machine (additional 10 electrodes), and then draw blood to measure cardiac biomarkers, repeated every 4-6 hours during 18-24 hours of observation. VectraCor will perform all three processes above to detect an AMI within seconds and derive the 12-22 lead ECG from the cardiac monitor using only 5 electrodes, thus eliminating the immediate need for the ECG machine and blood draw resulting in reduced costs, time and labor and more importantly faster physician intervention to treat the patient. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members